Therefore, combination with PD-1 or PD-L1 monoclonal antibodies or editing out PD-1 (PD-1 KO) may noticeably enhance the antitumor activity of cytotoxic T lymphocytes (CTLs), enable T cells to recognize tumor cells, promote tumor cell eradication and reduce T-cell exhaustion. This evidence concerns the gene CD274 and neoplasm.